First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC)

P.  Turner; S. Jain; A. Cole; S. Biggart; A. Hounsell; J. O'Sullivan

doi:10.1016/j.clon.2020.01.011

First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC)

P. Turner, S. Jain, A. Cole, S. Biggart, A. Hounsell, J. O'Sullivan

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.

Original language	English
Pages (from-to)	e130-e131
Journal	Clinical Oncology
Volume	32
Issue number	5
Early online date	31 Mar 2020
DOIs	https://doi.org/10.1016/j.clon.2020.01.011
Publication status	Published - May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2020.01.011Licence: Unspecified

Cite this

@article{f681104250814fb681737f7b3db2c64c,

title = "First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC)",

abstract = "Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.",

author = "P. Turner and S. Jain and A. Cole and S. Biggart and A. Hounsell and J. O'Sullivan",

year = "2020",

month = may,

doi = "10.1016/j.clon.2020.01.011",

language = "English",

volume = "32",

pages = "e130--e131",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC)

AU - Turner, P.

AU - Jain, S.

AU - Cole, A.

AU - Biggart, S.

AU - Hounsell, A.

AU - O'Sullivan, J.

PY - 2020/5

Y1 - 2020/5

N2 - Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.

AB - Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.

U2 - 10.1016/j.clon.2020.01.011

DO - 10.1016/j.clon.2020.01.011

M3 - Meeting abstract

SN - 0936-6555

VL - 32

SP - e130-e131

JO - Clinical Oncology

JF - Clinical Oncology

IS - 5

ER -

First survival data from the ADRRAD clinical trial; pelvic radiotherapy and concurrent radium-223 in metastatic hormone sensitive prostate cancer (mHSPC)

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this